Comparing generic abaloparatide to Tymlos® in healthy adults
Part of Bones, joints & muscles, Hormones & metabolism clinical trials.
This study tests whether a generic version of the osteoporosis drug abaloparatide (Tymlos®) works the same as the brand-name version. It is for healthy adults aged 40–65 who are not taking other medications and can follow a controlled diet and lifestyle.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 65 years old.
- You are generally healthy with no major medical conditions (like heart, liver, kidney, or bone disease).
- You are not pregnant, breastfeeding, or planning pregnancy in the next 6 months.
- You have no known allergies to the study drug or similar medications.
- You do not have high calcium levels, kidney stones, or gout.
- You can avoid certain foods (like grapefruit, coffee) and alcohol during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called SAL023 to see how it compares to an approved drug (Evenity) in healthy people. It looks at how the body processes the drug, safety, and immune response. You must be healthy, within a certain age and weight range, and not have any bone or heart problems.
This study tests a medication called tirzepatide (a type of GLP-1 drug) to see how it affects muscle and bone health during weight loss. It is for people with obesity who are not menopausal and do not have diabetes or bone disease.
This study is a follow-up for people who completed a previous precision medicine trial for osteoporosis. It will monitor your bone health to see how well the treatment is working over time.
This trial tests whether switching between two medications (Romosozumab and Denosumab) using a cycle or sequence schedule works better for improving bone density in postmenopausal women with severe osteoporosis. It aims to find the most effective treatment plan.
This trial is studying whether the time of day you receive teriparatide (a bone-building drug) affects its effectiveness for postmenopausal women with osteoporosis. You may be eligible if you have very low bone density, are between 60 and 70, and are at least 5 years past your last period.
This trial tests a new injection called abaloparatide (QLG2128) for women after menopause who have weak bones (osteoporosis) and a high risk of breaking a bone. It aims to see if it helps strengthen bones and prevent fractures.
Hear when a new Osteoporosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.